BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33323859)

  • 1. PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
    Jenkins TM; Cantrell LA; Stoler MH; Mills AM
    Int J Gynecol Pathol; 2021 Nov; 40(6):563-574. PubMed ID: 33323859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review.
    Jenkins TM; Hanley KZ; Schwartz LE; Cantrell LA; Stoler MH; Mills AM
    Am J Surg Pathol; 2020 Jun; 44(6):782-792. PubMed ID: 31934920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.
    Jenkins TM; Cantrell LA; Stoler MH; Mills AM
    Am J Surg Pathol; 2022 Apr; 46(4):435-442. PubMed ID: 35125452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
    Pinto A; Mackrides N; Nadji M
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
    Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
    Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Mismatch Repair-deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas.
    Segura SE; Pedra Nobre S; Hussein YR; Abu-Rustum NR; Weigelt B; Soslow RA; DeLair DF
    Am J Surg Pathol; 2020 Nov; 44(11):1573-1579. PubMed ID: 32804882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas.
    Taylor NP; Gibb RK; Powell MA; Mutch DG; Huettner PC; Goodfellow PJ
    Gynecol Oncol; 2006 Jan; 100(1):107-10. PubMed ID: 16169065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
    Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
    Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
    Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
    Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medullary carcinoma of the ampulla has distinct clinicopathologic characteristics including common association with microsatellite instability and PD-L1 expression.
    Xue Y; Balci S; Pehlivanoglu B; Muraki T; Memis B; Saka B; Kim G; Bandyopadhyay S; Knight J; El-Rayes B; Kooby D; Maithel SK; Sarmiento J; Basturk O; Reid MD; Adsay V
    Hum Pathol; 2023 Jan; 131():38-46. PubMed ID: 36502926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
    Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
    Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
    Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
    Rowe M; Krishnan R; Mills A; Ring K
    Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
    Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
    Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Features Associated with Microsatellite Instability/Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Quantitative Systematic Review.
    Travaglino A; Raffone A; Santoro A; Raimondo D; Orsini B; Casadio P; Zullo F; Seracchioli R; Zannoni GF; Insabato L; Mollo A
    Pathobiology; 2022; 89(4):198-204. PubMed ID: 35231921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
    Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.